Skip to main content
. 2020 Oct 29;10:570340. doi: 10.3389/fonc.2020.570340

Figure 3.

Figure 3

FBLN2 immunohistochemistry. Representative sections of non-tumor (A,B), non-invasive (Ta) (C,D), superficial (T1) (E,F), and muscle-invasive urothelial carcinoma (T2) (G,H) demonstrate stepwise increments in FBLN2 expression (original magnification: 200× and 400×).